AR030346A1 - Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico - Google Patents

Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico

Info

Publication number
AR030346A1
AR030346A1 ARP010103847A ARP010103847A AR030346A1 AR 030346 A1 AR030346 A1 AR 030346A1 AR P010103847 A ARP010103847 A AR P010103847A AR P010103847 A ARP010103847 A AR P010103847A AR 030346 A1 AR030346 A1 AR 030346A1
Authority
AR
Argentina
Prior art keywords
treatment
retina
head
neurodegenerative disorders
optical nerve
Prior art date
Application number
ARP010103847A
Other languages
English (en)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR030346A1 publication Critical patent/AR030346A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se describe el uso de ácidos 3-benzoilfenilacéticos y derivados, incluyendo nepafenac, para el tratamiento de desordenes retinales neurodegenerativos.
ARP010103847A 2000-08-14 2001-08-10 Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico AR030346A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22513200P 2000-08-14 2000-08-14

Publications (1)

Publication Number Publication Date
AR030346A1 true AR030346A1 (es) 2003-08-20

Family

ID=22843666

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103847A AR030346A1 (es) 2000-08-14 2001-08-10 Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico

Country Status (17)

Country Link
US (1) US6638976B2 (es)
EP (1) EP1309322B1 (es)
JP (1) JP2004506010A (es)
AR (1) AR030346A1 (es)
AT (1) ATE330596T1 (es)
AU (1) AU8125801A (es)
BR (1) BR0113201A (es)
CA (1) CA2418059C (es)
CY (1) CY1106155T1 (es)
DE (1) DE60120990T2 (es)
DK (1) DK1309322T3 (es)
ES (1) ES2266229T3 (es)
HK (1) HK1057332A1 (es)
MX (1) MXPA03001160A (es)
PT (1) PT1309322E (es)
TW (1) TWI286933B (es)
WO (1) WO2002013805A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132773A1 (en) * 2001-08-13 2004-07-08 Gamache Daniel A Method of treating neurodgenerative disorders of the retina and optic nerve head
RU2006101150A (ru) * 2003-06-13 2006-06-10 Алькон, Инк. (Ch) Композиции нестероидных противовоспалительных средств для лечения патологического ангиогенеза глаз
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
AU2006244245B2 (en) * 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
ZA200709251B (en) * 2005-05-10 2009-08-26 Alcon Inc Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
RU2458656C1 (ru) * 2011-06-17 2012-08-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения оперированного незакрывшегося макулярного отверстия
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (es) 1967-07-31 1971-03-24
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4568695A (en) 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
DE3668450D1 (de) 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
CA1325382C (en) 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
JP3396953B2 (ja) 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6025353A (en) 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AU772705B2 (en) 1999-01-07 2004-05-06 Vanderbilt University Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors
US6426341B1 (en) 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US6413965B1 (en) 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6555540B1 (en) 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device

Also Published As

Publication number Publication date
DE60120990T2 (de) 2007-03-15
EP1309322B1 (en) 2006-06-21
WO2002013805A3 (en) 2002-05-30
HK1057332A1 (en) 2004-04-02
CA2418059C (en) 2009-12-22
JP2004506010A (ja) 2004-02-26
WO2002013805A2 (en) 2002-02-21
ES2266229T3 (es) 2007-03-01
DK1309322T3 (da) 2006-10-23
BR0113201A (pt) 2006-05-09
EP1309322A2 (en) 2003-05-14
AU8125801A (en) 2002-02-25
MXPA03001160A (es) 2004-08-02
PT1309322E (pt) 2006-11-30
US6638976B2 (en) 2003-10-28
CA2418059A1 (en) 2002-02-21
TWI286933B (en) 2007-09-21
CY1106155T1 (el) 2011-06-08
DE60120990D1 (de) 2006-08-03
US20020049255A1 (en) 2002-04-25
ATE330596T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
FI9630U1 (fi) Järjestelmä potilaan silmän verkkokalvon hoitamiseksi laserilla
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
EE05036B1 (et) Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
DOP2002000429A (es) Imidazotriazinas
DK1263504T3 (da) Anvendelse af forbindelser med 5-HT1A aktivitet, som er anvendelige til behandling af lidelser i den ydre retina
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
AR030345A1 (es) Metodo de tratamiento de desordenes relacionados con angiogenesis
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
ES2171233T3 (es) Uso de eliprodil para la preparacion de un medicamento para el tratamiento de trastornos isquemicos de la retina o el nervio optico.
EA200001246A1 (ru) Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
WO2002078681A3 (en) Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
BR0309747A (pt) Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial
ES2188742T3 (es) Trapidil para uso en la terapia de cuadros patologicos influenciables por la inmunomodulacion.

Legal Events

Date Code Title Description
FC Refusal